BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21304968)

  • 1. Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation.
    Colak G; Keillor JW; Johnson GV
    PLoS One; 2011 Jan; 6(1):e16665. PubMed ID: 21304968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular localization and conformational state of transglutaminase 2: implications for cell death.
    Gundemir S; Johnson GV
    PLoS One; 2009 Jul; 4(7):e6123. PubMed ID: 19568436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transglutaminase 2 facilitates or ameliorates HIF signaling and ischemic cell death depending on its conformation and localization.
    Gundemir S; Colak G; Feola J; Blouin R; Johnson GV
    Biochim Biophys Acta; 2013 Jan; 1833(1):1-10. PubMed ID: 23085038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transglutaminase 2: a molecular Swiss army knife.
    Gundemir S; Colak G; Tucholski J; Johnson GV
    Biochim Biophys Acta; 2012 Feb; 1823(2):406-19. PubMed ID: 22015769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.
    Kumar A; Xu J; Sung B; Kumar S; Yu D; Aggarwal BB; Mehta K
    Breast Cancer Res; 2012 Jan; 14(1):R4. PubMed ID: 22225906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transglutaminase 2 protects against ischemic insult, interacts with HIF1beta, and attenuates HIF1 signaling.
    Filiano AJ; Bailey CD; Tucholski J; Gundemir S; Johnson GV
    FASEB J; 2008 Aug; 22(8):2662-75. PubMed ID: 18375543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using FLIM-FRET to measure conformational changes of transglutaminase type 2 in live cells.
    Caron NS; Munsie LN; Keillor JW; Truant R
    PLoS One; 2012; 7(8):e44159. PubMed ID: 22952912
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete transglutaminase 2 ablation results in reduced stroke volumes and astrocytes that exhibit increased survival in response to ischemia.
    Colak G; Johnson GV
    Neurobiol Dis; 2012 Mar; 45(3):1042-50. PubMed ID: 22198379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Differential Effects of R580A Mutation on Transamidation and GTP Binding Activity of Rat and Human Type 2 Transglutaminase.
    Ruan Q; Tucholski J; Gundemir S; Johnson Voll GV
    Int J Clin Exp Med; 2008; 1(3):248-59. PubMed ID: 19079660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transglutaminase 2: Friend or foe? The discordant role in neurons and astrocytes.
    Quinn BR; Yunes-Medina L; Johnson GVW
    J Neurosci Res; 2018 Jul; 96(7):1150-1158. PubMed ID: 29570839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depletion of astrocytic transglutaminase 2 improves injury outcomes.
    Monteagudo A; Feola J; Natola H; Ji C; Pröschel C; Johnson GVW
    Mol Cell Neurosci; 2018 Oct; 92():128-136. PubMed ID: 29969654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.
    Kerr C; Szmacinski H; Fisher ML; Nance B; Lakowicz JR; Akbar A; Keillor JW; Lok Wong T; Godoy-Ruiz R; Toth EA; Weber DJ; Eckert RL
    Oncogene; 2017 May; 36(21):2981-2990. PubMed ID: 27941875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional characterization of naturally occurring transglutaminase 2 mutants implicated in early-onset type 2 diabetes.
    Salter NW; Ande SR; Nguyen HK; Nyomba BL; Mishra S
    J Mol Endocrinol; 2012 Jun; 48(3):203-16. PubMed ID: 22394545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue transglutaminase is a multifunctional BH3-only protein.
    Rodolfo C; Mormone E; Matarrese P; Ciccosanti F; Farrace MG; Garofano E; Piredda L; Fimia GM; Malorni W; Piacentini M
    J Biol Chem; 2004 Dec; 279(52):54783-92. PubMed ID: 15485857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transglutaminase 2: a multi-functional protein in multiple subcellular compartments.
    Park D; Choi SS; Ha KS
    Amino Acids; 2010 Aug; 39(3):619-31. PubMed ID: 20148342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological, pathological, and structural implications of non-enzymatic protein-protein interactions of the multifunctional human transglutaminase 2.
    Kanchan K; Fuxreiter M; Fésüs L
    Cell Mol Life Sci; 2015 Aug; 72(16):3009-35. PubMed ID: 25943306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transglutaminase 2 modulation of NF-κB signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury.
    Feola J; Barton A; Akbar A; Keillor J; Johnson GVW
    Brain Res; 2017 Aug; 1668():1-11. PubMed ID: 28522262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TG2 transamidating activity acts as a reostat controlling the interplay between apoptosis and autophagy.
    Rossin F; D'Eletto M; Macdonald D; Farrace MG; Piacentini M
    Amino Acids; 2012 May; 42(5):1793-802. PubMed ID: 21479826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Transglutaminase 2 in Cell Death, Survival, and Fibrosis.
    Tatsukawa H; Hitomi K
    Cells; 2021 Jul; 10(7):. PubMed ID: 34360011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of Transglutaminase 2 conformational changes in living cell.
    Pavlyukov MS; Antipova NV; Balashova MV; Shakhparonov MI
    Biochem Biophys Res Commun; 2012 May; 421(4):773-9. PubMed ID: 22548802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.